Expertise in
2
conditions

Claire Berger

Saint-etienne-de-valoux, FR 
Expertise in
2
conditions
Saint-etienne-de-valoux, FR 

Overview

Claire Berger practices practicing medicine in Saint-etienne-de-valoux, France.

Ms. Berger is highly rated in 2 conditions, according to our data. Her clinical expertise encompasses Blood Clots, Severe Congenital Neutropenia, Exocrine Pancreatic Insufficiency, Oophorectomy, and Bone Marrow Transplant.

She is actively involved in clinical research, co-authoring 118 peer reviewed articles and participating in 9 clinical trials.

Gender

Female

Locations

Saint-etienne-de-valoux, France
Other Locations
Paris, 75006, France
Saint Étienne, France
Saint-jean-saint-germain, France
Bordeaux, France
Metz, 57070, France
Lyon, France
Saint-priest-la-vetre, France
Grenoble, 38042, France
Villejuif, France
Saint-etienne, France
Poitiers, France
Nantes, France

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

9 Clinical Trials

A Phase 3b, Prospective, Open-label, Multicenter, Single Treatment Arm, Continuation Study of the Safety and Efficacy of TAK-755 (rADAMTS13, Also Known as BAX 930/SHP655) in the Prophylactic and On-demand Treatment of Subjects With Severe Congenital Thrombotic Thrombocytopenic Purpura (cTTP; Upshaw-Schulman Syndrome, or Hereditary Thrombotic Thrombocytopenic Purpura)
A Phase 3b, Prospective, Open-label, Multicenter, Single Treatment Arm, Continuation Study of the Safety and Efficacy of TAK-755 (rADAMTS13, Also Known as BAX 930/SHP655) in the Prophylactic and On-demand Treatment of Subjects With Severe Congenital Thrombotic Thrombocytopenic Purpura (cTTP; Upshaw-Schulman Syndrome, or Hereditary Thrombotic Thrombocytopenic Purpura)
Enrollment Status: Active_not_recruiting
Publish Date: April 02, 2026
Intervention Type: Biological
Study Drug: TAK-755
Study Phase: Phase 3
A Phase 3, Prospective, Randomized, Controlled, Open-label, Multicenter, 2 Period Crossover Study With a Single Arm Continuation Evaluating the Safety And Efficacy of BAX 930 (rADAMTS13) in the Prophylactic And On-demand Treatment of Subjects With Severe Congenital Thrombotic Thrombocytopenic Purpura (cTTP, Upshaw-Schulman Syndrome [USS], Hereditary Thrombotic Thrombocytopenic Purpura [hTTP])
A Phase 3, Prospective, Randomized, Controlled, Open-label, Multicenter, 2 Period Crossover Study With a Single Arm Continuation Evaluating the Safety And Efficacy of BAX 930 (rADAMTS13) in the Prophylactic And On-demand Treatment of Subjects With Severe Congenital Thrombotic Thrombocytopenic Purpura (cTTP, Upshaw-Schulman Syndrome [USS], Hereditary Thrombotic Thrombocytopenic Purpura [hTTP])
Enrollment Status: Completed
Publish Date: February 09, 2026
Intervention Type: Biological
Study Drug: BAX930
Study Phase: Phase 3
Personalized Massive Online Open Course After Childhood Cancer: Impact Study START-MOOC2
Personalized Massive Online Open Course After Childhood Cancer: Impact Study START-MOOC2
Enrollment Status: Active_not_recruiting
Publish Date: February 10, 2025
Intervention Type: Other
Study Phase: Not Applicable
Pan-genome Analysis of Neuroblastoma by Comparative Genomic Hybridization and Correlation With Pathology for the Diagnostic and the Prognostic Classification
Pan-genome Analysis of Neuroblastoma by Comparative Genomic Hybridization and Correlation With Pathology for the Diagnostic and the Prognostic Classification
Enrollment Status: Completed
Publish Date: December 01, 2023
Intervention Type: Procedure
Study Phase: Not Applicable
Determinants and Consequences of the Transition to Adulthood Among Adolescents With Haemophilia - TRANSHEMO
Determinants and Consequences of the Transition to Adulthood Among Adolescents With Haemophilia - TRANSHEMO
Enrollment Status: Completed
Publish Date: February 14, 2023
Intervention Type: Other
A Multicenter Study to Evaluate a Risk-adapted Strategy for Treatment of Extra Cranial Non Seminomateous Malignant Germ Cell Tumour in Children and Adolescent
A Multicenter Study to Evaluate a Risk-adapted Strategy for Treatment of Extra Cranial Non Seminomateous Malignant Germ Cell Tumour in Children and Adolescent
Enrollment Status: Completed
Publish Date: August 29, 2022
Intervention Type: Drug
Study Drugs: Velbe+Bleomycin+Cisplatin, Vepeside+Ifosfamide+Cisplatin
Study Phase: Phase 2
International Randomized Phase II Trial of the Combination of Vincristine and Irinotecan With or Without Temozolomide (VI or VIT) in Children and Adults With Refractory or Relapsed Rhabdomyosarcoma
International Randomized Phase II Trial of the Combination of Vincristine and Irinotecan With or Without Temozolomide (VI or VIT) in Children and Adults With Refractory or Relapsed Rhabdomyosarcoma
Enrollment Status: Completed
Publish Date: September 18, 2019
Intervention Type: Drug
Study Phase: Phase 2
SALTO -2 ( Long Term Monitoring In Oncology ) : Getting Long-term Management of Adult Children Cured of Childhood Cancer in Rhône-Alpes, Multicentric Study
SALTO -2 ( Long Term Monitoring In Oncology ) : Getting Long-term Management of Adult Children Cured of Childhood Cancer in Rhône-Alpes, Multicentric Study
Enrollment Status: Completed
Publish Date: October 22, 2018
Intervention Type: Other
Immunomonitoring of Children With Neuroblastoma for the Development of Antitumor Immunotherapy Strategies
Immunomonitoring of Children With Neuroblastoma for the Development of Antitumor Immunotherapy Strategies
Enrollment Status: Unknown
Publish Date: August 23, 2018
Intervention Type: Other
Study Phase: Not Applicable
View 8 Less Clinical Trials

118 Total Publications

Ensuring equitable access to information after pediatric cancer: Ethical perspectives from the E-QuoL project.
Ensuring equitable access to information after pediatric cancer: Ethical perspectives from the E-QuoL project.
Journal: Bulletin du cancer
Published: October 15, 2025

Frequently Asked Questions about Claire Berger

Is Claire Berger a top-rated expert for Blood Clots?

MediFind is an objective health platform that identifies experts based on real-world data. Claire Berger is classified as an Advanced expert for Blood Clots, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Claire Berger participate in research or clinical trials?

Yes. Claire Berger has published 118 articles and abstracts on conditions like Blood Clots. You can view a list of Claire Berger's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ms. Berger's expertise for a condition
ConditionClose
      View All 49 Experienced Conditions
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile